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AbstrAct
Objective To report the incidence rate ratios (IRR) of acute 
myocardial infarctions (AMI) and cerebrovascular events 
(CVE) in incident SLE cases from a defined population. 
To study the risk factors for cardiovascular events in all 
patients with SLE at our unit.
Methods Patients with SLE diagnosed from 1981 to 
2006 were followed through to 2016. IRRs of AMI and CVE 
were calculated. The AMI and CVE incidence patterns for 
patients with SLE were studied in relation to hypertension, 
smoking, renal dysfunction, anticardiolipin (aCL) antibodies 
at diagnosis, disease duration and organ damage before 
an event.
Results 262 patients with SLE were included in the 
study; of these 175 were from the defined population. 
Overall, 37 AMI and 44 CVE were recorded. An increased 
IRR of 3 for AMI was found (p<0.001). Smoking, 
hypertension and reduced renal function were risk 
factors for AMI. An increased IRR of 3.3 for ischaemic 
CVE was found for women (p<0.001). Hypertension and 
aCL were risk factors for CVE. Organ damage before 
events was increased.
Conclusions Cardiovascular events are increased in 
SLE and are associated with hypertension, smoking and 
increased damage rate.
IntROduCtIOn
SLE is an autoimmune disorder with multiple 
organ manifestations. Morbidity in early 
disease is characterised by active inflam-
matory processes, while later morbidity is 
primarily as a consequence of long- standing 
inflammation or treatment with corticos-
teroids leading to organ damage, especially 
cardiovascular disease (CVD). The same 
bimodal pattern was described in the 1970s 
for mortality, with active disease or infec-
tions involved with shorter disease duration 
and acute myocardial infarctions (AMI) 
and possibly cerebrovascular events (CVE) 
after longer disease duration.1 2 With better 
understanding of the disease mechanisms 
and more judicious use of different thera-
peutic modalities these patterns of manifes-
tations might have changed as some reports 
indicate.3 However, a meta- analysis of 
mortality in SLE indicates that cardiovascular 
issues remain problematic.4 The morbidity 
for AMI has been shown to be increased 
with the range 2–50 times in reports from 
many countries, but with different study 
populations and stratifications.5–8 Many 
have also reported an increased frequency 
of CVE in SLE, and recent studies indicate 
that this is often an early manifestation, and 
part of the antiphospholipid syndrome.9–12 
Contrary to previous literature, also AMI has 
now been reported to occur early after diag-
nosis of SLE, or in some cases even before 
diagnosis.11 13 Regarding CVD in SLE the 
most striking finding has been the relatively 
higher frequency of this manifestation in 
women before menopause, a group in the 
general population which often is consid-
ered to be protected.5 8 14
The proposed risk factors responsible for 
the observed increase of CVD in SLE are 
both standard risk factors such as hyper-
tension, hyperlipidaemia, smoking and 
diabetes,8 15–17 and SLE specific. Among the 
proposed SLE- specific risk factors are disease 
activity, glucocorticoid use, cytostatic treat-
ment, lupus nephritis, SLE disease duration 
and antiphospholipid antibodies.14–20 It has 
also been reported that SLE- related factors 
are seen early in the disease course while 
traditional risk factors accrue over time.21
The aim of this series was to study the 
frequencies of myocardial infarction and 
CVEs in patients diagnosed with SLE within 
a defined population. In addition, we wanted 
to analyse the cardiovascular events in rela-
tion to age at diagnosis, disease duration, 
accumulated damage before the event and 
any relationship with the risk factors hyper-
tension and smoking. For risk factor analysis 
our entire cohort, also including referred 
patients with SLE from areas outside the 
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Population under study
A population- based SLE cohort study was initiated in 
1981 including all known incident SLE cases in a defined 
local catchment area of eight counties, with an average 
population of 196 000 individuals, and surrounding the 
city of Lund. The completeness of case retrieval in this 
area has been verified by capture- recapture technique 
from multiple sources.22 The cohort is continuously 
collected and patients are followed prospectively at the 
Skåne University Hospital, Unit of Rheumatology. This 
well- defined cohort was used for calculation of rate ratios 
of cardiovascular events compared with the general popu-
lation of the same area, stratified for sex and age. For all 
other analyses, where a population comparator was not 
included, also SLE cases from outside the defined area 
were included. On each case American College of Rheu-
matology (ACR) classification criteria for SLE,23–25 IgG 
anticardiolipin antibodies, presence of the standard risk 
factors hypertension, smoking and diabetes, all at diag-
nosis, were registered. Organ damage has been regis-
tered each year up to event (AMI or CVE) with Systemic 
Lupus International Collaborating Clinics (SLICC)/ACR 
damage index (DI).26 For comparison of organ damage 
up to event each SLE case with event was matched for sex, 
age at diagnosis and disease duration, with two patients 
with SLE without event. When this study was planned, 
four decades ago, no patient partnership was included.
data retrieval
The responsibility for healthcare in Sweden is decentral-
ised to different regions and their regional county coun-
cils. Both public and private healthcare is available where 
the only difference lies in the organisation; all health-
care in Sweden is funded through taxes and the same 
costs apply to the individual regardless whether the care 
is provided from a public institution or from a private 
healthcare provider. In the Region of Skåne, the south-
ernmost part of Sweden, electronic healthcare informa-
tion is available since 1998 including all hospitalisations 
for the population, and all visits at both hospital clinics 
and in primary care. This database, the Skåne Healthcare 
Register, contains information on International Classifi-
cation of Diseases (ICD) codes for each contact.
Only incident cases with a new diagnosis of SLE between 
1 January 1981 and 31 December 2006 were included. 
In all, 262 patients with SLE were included in the study 
(175 patients with SLE from the local cohort with a mean 
annual prevalence of 115 patients in the defined area). 
Since only incident cases after 1981 were included, the 
annual prevalence increased and reached a steady state 
in 1998 in the defined area, a prerequisite for calculation 
of rate ratios. (online supplementary figure 1). Only two 
known patients with SLE in the area refused to partici-
pate in our clinic, but we were allowed to follow their data 
in the registries, so they were not lost to follow- up.
The ICD codes in the ICD 10th Revision chapter for 
cardiovascular disorders were extracted for all patients 
with SLE with events during the period 1 January 1998 to 
31 December 2016 and the codes I21 (AMI), I60, I61, I62, 
I63 and I64 (all CVEs) were analysed, taken into account 
only the first AMI and/or CVE diagnosis for each patient. 
Only events after the diagnosis of SLE were included, 
and in fact no events occurred before diagnosis of SLE. 
Events from the time period 1981–1997 were traced in 
the medical records. If a patient has had both an AMI 
and a CVE the first event of both categories is included 
in the analysis. The frequencies of the same diagnoses 
in the population of the defined area during the same 
period, stratified for sex, age and calendar year, were also 
extracted and used for calculation of rates and rate ratios.
In addition, medical records for all patients with SLE 
were scrutinised for verification of SLE diagnosis, defined 
previously,14 and for cardiovascular events, defined as 
patients fulfilling the SLICC/ACR- DI.26 Hypertension 
was defined as a systolic blood pressure >140 mm Hg and/
or a diastolic blood pressure >90 mm Hg and/or present 
treatment for hypertension. Smoking data were recorded 
as ever smoking before event. Reduced glomerular filtra-
tion rate before event was defined by the SLICC/ACR- 
DI. Obesity and dyslipidaemia were not included in the 
analysis since they were only registered from 1990, why 
data from time of diagnosis were not available in cases 
diagnosed earlier. Follow- up ended 31 December 2016 or 
earlier if the patient was deceased, moved out of the area 
or was lost to follow- up.
statistical analysis
Incidence rates of AMI and CVE per 1000 person- years 
were calculated. Age and sex- standardised rate ratios with 
95% CIs were calculated comparing SLE and non- SLE 
in the defined area under study. Associations with risk 
factors, and disease manifestations were determined with 
non- parametric statistics, Mann- Whitney U- test was used 
when comparing groups including matched pairs, or 
parametric statistics, Student’s t- test, when appropriate. 
For the matched pairs, when analysing the frequency of 
damage before event, a patient with SLE with an event 
was matched with one or two patients with SLE without 
the event for the same age at diagnosis (±3 years), same 
sex and same disease duration. A significance level of 
0.05 was applied if nothing else is stated. Analysis was 
done using Statistica V.6.0. We used multivariable Cox 
regression to examine the possible influence of different 
covariates, other than the accumulated damage described 
above, on time to cardiovascular events. These statistical 
calculations were performed using RStudio V.1.1.456.
Results
In total, 262 patients with SLE diagnosed between 1981 
and 2006 were included. Of these, 175 lived in the 
defined catchment area of the local cohort. In the local 
cohort the prevalence for SLE was stable during the 
period 1998–2016 with a mean annual number of 115 
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Table 1a Demographic data and risk factors in the total 
SLE cohort
Variable Patients with SLE
n total 262
  Females 224 (86%)
Mean age (range) 43.4 years (10–88)
Hypertension 39/262 (15%)
Smoking ever (before event) 71/118 (60%)
Diabetes   1/262








n total 175 196 259 (age 
>17 years)





59   
Females 101 (88%)
Mean age (range) 48.3 years 
(15–88)
40.3 years (0 to 100+)
individuals. For women, the prevalence was 101 per 100 
000 women. Patient and population demographic data 
and potential risk factors for CVD present at diagnosis are 
given in tables 1a and b. All patients in the defined area 
were Caucasian except one of Asian origin. No cases were 
lost to follow- up.
In total, 37 AMI cases among patients with SLE were 
registered. Of these, 16 occurred in the defined cohort 
during the period 1998–2016 and were used for calcula-
tion of rate ratios. There were 44 cases of CVE among the 
patients with SLE and of these 21 occurred in the defined 
cohort between 1998 and 2016. Both AMI and CVE were 
registered in 10 cases, six of these in the defined cohort. 
In seven of these cases, with both CVE and AMI, the CVE 
preceded the AMI by at least 2 years (range 2–26 years) 
and for the remaining three cases, with the AMI first, the 
time difference was at least 4 years (range 4–9 years). In 
total, there were 81 first events in 71 patients with SLE. 
The total follow- up time was 5560 patient- years, of these 
3553 patient- years were in the cohort from the defined 
area with median disease duration and also mean dura-
tion from inclusion of 19 years (range 1–36 years, SD=8.7).
The incidence rate ratios (IRR) for first myocardial 
infarction (AMI) are given in table 2. In summary, the 
IRR for AMI was 3.0 in SLE (95% CI 1.3 to 6.9, p<0001), 
and the increased rate was most pronounced for women 
below 60 years of age. An increased rate was only seen in 
males in the age group 40–59 years where the increased 
rate was 7.7 (95% CI 1.5 to 39.9, p<0.001). There were no 
significant increased rates in ages 60 years or older, for 
neither women nor for men.
The incidence pattern for myocardial infarction in rela-
tion to SLE duration in all patients (n=262) is illustrated 
in figure 1. The increased incidence of AMI early after 
diagnosis of SLE was seen in patients with an SLE diag-
nosis at age of or above 60 years (median duration 4 years, 
range 0–30 years), while the increased AMI frequency 
in patients younger than 60 years of age occurred after 
longer disease duration (median duration 20 years, range 
0–32 years). This difference was significant (p<0.01). 
Premenopausal female patients with SLE younger than 
55 years of age had their first AMI after a median disease 
duration of 20 years, while patients 55 years or older had 
their first AMI after a median disease duration of only 
7 years (p<0.05).
The IRRs for ischaemic CVE are given in table 3. An IRR 
of 3.3 for CVE in women with a diagnosis of SLE indicated 
an increased rate (95% CI 2.4 to 4.6, p<0.001). The inci-
dence pattern for first CVE in relation to SLE duration 
in all patients is shown in figure 2, and the majority of 
events occurred during the first 10 years after diagnosis. 
Of the 44 first CVE, three are registered as subarachnoid 
bleeding and six as intracerebral bleeding; the remaining 
35 events were classified as ischaemic CVE (data not 
shown).
Selected risk factors for AMI and CVE, presented at 
diagnosis of SLE, are listed in table 1. Smoking ever was 
seen more often in patients who eventually developed 
AMI (non- parametric statistics, p=0.01). In multivari-
able regression only gender and hypertension at diag-
nosis remained in the analysis due to many missing data 
for smoking. Hypertension was more common both for 
AMI and CVE as compared with patients without events 
(tables 4a and b), but for those who developed AMI this 
was true only for patients with AMI before an age of 55 
years (online supplementary figure 2a–d). Mean time to 
an event was 4.8 years (n=21, SD 5.96) for patients with 
SLE and hypertension compared with 12.4 years (n=17, 
SD 11.24) for patients without hypertension (p<0.01).
Our study indicates that in patients with SLE reduced 
glomerular filtration rate (<50 mL/min) was associated 
with AMI (p<0.05). The presence of positive IgG anticar-
diolipin antibodies was associated with CVE (p<0.05).
Organ damage was measured by SLICC/ACR- DI. In 
our study, the SLICC/ACR- DI scores were extracted for 
patients with SLE who subsequently had an event and for 
two matched patients with SLE without events. The values 
extracted were 87 points for the 37 AMI cases (median 1) 
and 100 points for the 73 matched patients with SLE with 
no AMI (median 1). Similarly, the SLICC/ACR- DI scores 
before first CVE were 88 points in the 44 cases (median 
2) and 70 points in 74 matched patients with SLE with no 
CVE (median 1). A higher SLICC/ACR damage score was 
associated with a higher rate of event (AMI p=0.03, CVE 
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Table 2 Incidence rate ratio for myocardial infarction in SLE 1998–2016
Age at event
All ages Age <40 years Ages 40–59 years Age ≥60 years
SLE Non- SLE SLE Non- SLE SLE Non- SLE SLE Non- SLE
Both sexes
n (mean prevalence) 115 196 259 18 77 294 40 65 211 57 53 754
Events 16 9051 1 66 3 1256 12 7729
Incidence ratio/1000 
patient- years
7.3 2.4 2.9 0.9 3.9 1.0 11.1 7.6













n 101 99 425 15 37 806 36 32 535 50 29 084
Events 14 3629 1 15 2 281 11 3333
IR/1000 patient- years 7.3 1.9 3.5 0.02 2.9 0.5 11.6 6.0













n 14 96 834 3 39 488 4 32 676 7 24 670
Events 2 5422 0 51 1 975 1 4396
IR/1000 patient- years 7.5 2.9 – – 12.1 1.6 7.52 9.4









IR, incidence rate; IRR, incidence rate ratio; n.s., not significant.
Figure 1 SLE disease duration related to incidence rates for 
first myocardial infarction in the total SLE cohort and based 
on patients with an SLE diagnosis between 1981 and 2006 
and followed through to 2016 (n=262 patients). IR, incidence 
rate.
CVD events had an increased rate of pre- existing irrevers-
ible organ damage before the actual event.
dIsCussIOn
In this cohort study analysing the rate of CVD in patients 
with SLE we confirmed previous findings of increased 
rates of both AMI and CVE seen in this disorder, espe-
cially in women and for AMI also in women before 
menopause.5 8 10 12 15 16 18 Males are few and have only two 
ischaemic CVE events in the higher age group.
A major strength of this study was the long follow- up 
since cardiovascular events do not necessarily develop 
shortly after SLE debut. A second strength was the 
comprehensive registries available, both for research 
within our unit and for the healthcare registries in the 
region with complete coverage since 1998. Another 
advantage was the population- based approach with all 
known SLE cases in a defined area collected prospec-
tively since 1981, rendering an expanding cohort, stable 
from 1998, representative for SLE and thus allowing firm 
conclusions about frequencies, at least in populations 
with similar ethnicity and healthcare access.
Interestingly, we found that younger patients with 
SLE seem to have an increased rate of AMI after long 
disease duration. Older patients, on the contrary, expe-
rienced AMI, shortly after receiving their SLE diagnosis 
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Table 3 Incidence rate ratio for ischaemic cerebrovascular disorder in SLE 1998–2016
Age at event
All ages Age <40 years Ages 40–59 years Age ≥60 years
SLE Non- SLE SLE Non- SLE SLE Non- SLE SLE Non- SLE
Both sexes
n (mean prevalence) 115 196 259 18 77 294 40 65 211 57 53 754
Events 16 8457 0 169 4 910 12 7424
Incidence ratio/1000 
patient- years
4.5 2.2 – – 5.3 0.71 11.0 7.3










n 101 99 425 15 37 806 36 32 535 50 29 084
Events 14 4115 0 56 4 313 10 3746
IR/1000 patient- years 7.3 2.2 – – 5.8 0.5 10.5 6.8










n 14 96 834 3 39 488 4 32 676 7 24 670
Events 2 4342 0 67 0 597 2 3778
IR/1000 patient- years 7.5 2.4 – – – – 15.0 7.8







IR, incidence rate; IRR, incidence rate ratio; n.s., not significant.
Figure 2 SLE disease duration related to incidence rates for 
first cerebrovascular event in the total SLE cohort and based 
on patients with an SLE diagnosis between 1981 and 2006 
and followed through to 2016 (n=262 patients). IR, incidence 
rate.









  Gender 2.258 1.021 4.996 0.004*
  Hypertension 2.099 1.081 4.078 0.029
*Shorter time to acute myocardial infarction (AMI) for males with 
SLE.
population. Organ damage was reported to be associated 
with increased CVD risk,27 and we found that the accu-
mulated organ damage was higher before first events, 
both for AMI and CVE, than among patients with SLE 
without such events. Noteworthy, the SLICC/ACR- DI is 
constructed without attribution, why other causes than 
SLE disease activity leading to damage might be of more 
importance in older patients getting AMI or CVE.
Both classical risk factors for CVD in SLE, such as hyper-
tension, smoking, obesity, hyperlipidaemia and immo-
bility, and SLE- specific risk factors have been proposed in 
the literature,17 and the prevalence of standard CVD risk 
factors was in fact higher in patients with SLE compared 
with healthy controls.28–30 In this series, hypertension and 
smoking at diagnosis were associated with events, smoking 
only for AMI and hypertension for both AMI and CVE. Of 
special interest was our finding that hypertension at diag-
nosis was associated with AMI only in patients diagnosed 
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  Gender 0.4878 0.1507 1.579 0.231
  Hypertension 2.5878 1.3807 4.85 0.003
importance of blood pressure measurement in the clin-
ical examination also of younger patients with SLE. The 
impact of other risk factors at diagnosis was not analysed 
in this series due to lack of information. Analysing risk 
factors over time was beyond the scope of this study.
Regarding SLE- associated risk factors the presence of 
anticardiolipin IgG antibodies was increased in patients 
with SLE and CVE in our study. This finding was not 
surprising; in fact we reported the association almost 30 
years ago,14 and it has been confirmed repeatedly since 
then and others have shown that it was most pronounced 
when two or more antibodies were present.31
Several recent studies point out lupus nephritis as a 
risk factor for CVD. In a Swedish case–control study, 
excess atherosclerosis was seen in the SLE subgroup 
with nephritis as compared with the non- nephritis 
patients with SLE.32 Furthermore, in a recent nationwide 
Danish study, patients with lupus nephritis displayed 
an increased frequency of AMI.18 In parallel, our study 
presents data suggesting that reduced glomerular filtra-
tion rate below 50 mL/min is associated with AMI. This 
renal damage could be a consequence of disease activity, 
especially in younger patients with SLE getting AMI, 
since active lupus nephritis is more common in younger 
patients.33 However, since the DI is without attribution 
other causes of low glomerular filtration rate cannot 
be ruled out. We could not reproduce a recent finding 
of diabetes as a risk factor for cardiovascular events in 
SLE,16 probably due to limited number of diabetes cases 
in our cohort.
In recent publications from Canada AMI was analysed 
from registries of SLE cases and one finding was that 
AMI occurred early in the disorder and could even occur 
before diagnosis of SLE.11 13 Our results indicated more 
of a bimodal frequency of AMI, with the early events in 
older patients and the later events in patients diagnosed 
at a younger age. This pattern was not possible to detect 
in the western Canadian study since the follow- up was 
too short. We have not specifically addressed that AMI 
might occur even before the diagnosis of SLE, and in 
fact no such events were seen in the cohort used for IRR 
calculation.
Noteworthy, possible limitations in our study are time- 
dependent changes such as therapeutic improvements 
possibly affecting the outcome. In parallel, the develop-
ment of better diagnostic modalities, for example, more 
advanced computer- analysed electrocardiography, MRI 
of the brain (generally available from 1990 in our 
hospital and partly replacing the more restrict used 
cerebral angiography) and new cardiac enzyme tests 
allowing more specific diagnosis of AMI. A thorough 
review of the clinical presentations in medical records by 
one of the authors (RFI) could to some extent compen-
sate for these changes in diagnostic accuracy. However, 
these diagnostic and therapeutic changes also affect the 
population and thus do not influence the IRR calcula-
tions. Another limitation was that the numbers needed 
for statistical analysis are not sufficient for separate 
analysis of subarachnoid haemorrhages or intracerebral 
bleedings, but since only hypertension was retained in 
the multivariable analysis and hypertension certainly is 
a risk factor for bleeding we decided to handle all CVE 
together. Lack of information on certain risk factors at 
diagnosis was another limitation.
In conclusion, cardiovascular events are increased in 
SLE and are associated with hypertension, smoking and 
increased damage rate. This indicates that preventive 
measures from diagnosis should include good control 
of blood pressure, smoking cessation and, in addition to 
controlling disease activity, therapy adjustments to reduce 
the damage rate.
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The article has been corrected since it was published online. In the published version, 
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The correct names have been amended as Ragnar Freyr Ingvarsson and Helena 
Tydén.
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